| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.83.4.1194 |
| P698 | PubMed publication ID | 2013141 |
| P50 | author | Milton Weinstein | Q30223679 |
| Anna N. A. Tosteson | Q110143968 | ||
| P2093 | author name string | L Goldman | |
| J Tsevat | |||
| L W Williams | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart disease | Q190805 |
| coronary artery disease | Q844935 | ||
| P304 | page(s) | 1194-1201 | |
| P577 | publication date | 1991-04-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Expected gains in life expectancy from various coronary heart disease risk factor modifications | |
| P478 | volume | 83 |
| Q35048588 | A cardiovascular disease policy model that predicts life expectancy taking into account socioeconomic deprivation. |
| Q52243536 | A cost-benefit analysis of a cardiovascular disease prevention trial, using folate supplementation as an example. |
| Q36691416 | A review of health care models for coronary heart disease interventions |
| Q34218151 | A scandal of inaction: how to help GPs implement evidence-based health promotion. |
| Q36468753 | An expert system for simulation of coronary heart disease risk factor interventions |
| Q42758872 | Assessing heart disease risk in primary care. Cholesterol lowering should be just one part of a multiple risk factor intervention |
| Q74198448 | Benefits of smoking cessation for longevity |
| Q24795084 | Beyond the Evidence of the New Hypertension Guidelines. Blood pressure measurement - is it good enough for accurate diagnosis of hypertension? Time might be in, for a paradigm shift (I) |
| Q43840186 | Cardiovascular risk factors as determinants of 25-year all-cause mortality in the seven countries study |
| Q45193908 | Changing myocardial infarction population characteristics: reasons and implications |
| Q73328482 | Cholesterol-lowering therapy for smokers and non-smokers: a life-table analysis |
| Q28200183 | Coronary heart disease policy models: a systematic review |
| Q71920813 | Coronary risk factor status after percutaneous transluminal coronary angioplasty |
| Q50586994 | Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C. |
| Q34076188 | Cost per millimeter of mercury lowering is a measure of economic value for antihypertensive agents |
| Q34444643 | Cost-effectiveness of antihypertensive treatment in patients 80 years of age or older in Switzerland: an analysis of the HYVET study from a Swiss perspective |
| Q37870094 | Cost-effectiveness of statins revisited: lessons learned about the value of innovation |
| Q36502502 | Cost-effectiveness of telemetry for hospitalized patients with low-risk chest pain |
| Q40780468 | Cost-effectiveness of treatments for chronic hepatitis C. |
| Q24796318 | Description and validation of a Markov model of survival for individuals free of cardiovascular disease that uses Framingham risk factors |
| Q42579997 | Does modern medicine increase life-expectancy: Quest for the Moon Rabbit? |
| Q33637856 | Early Childhood Investments Substantially Boost Adult Health |
| Q40538399 | Enlightened individual choice vs the public's health: rational prevention from whose perspective? |
| Q40198541 | Estimated public health impacts of changes in concentrations of fine particle air pollution in Canada, 2000 to 2011. |
| Q36219221 | Health and lifestyle: a saudi profile |
| Q53614592 | Health status and hypertension: a population-based study. |
| Q44520744 | Life-years gained from coronary heart disease mortality reduction in Scotland: prevention or treatment? |
| Q61192550 | Life-years gained from modern cardiological treatments and population risk factor changes in England and Wales, 1981-2000 |
| Q37671015 | Longevity in Slovenia: Past and potential gains in life expectancy by age and causes of death |
| Q74461563 | Modeling all-cause mortality: projections of the impact of smoking cessation based on the NHEFS. NHANES I Epidemiologic Follow-up Study |
| Q72248253 | Modifying serum lipids to prevent coronary heart disease: do we have a consensus? |
| Q33839893 | Pharmacoeconomic considerations in the management of hypertension |
| Q34725115 | Plasma lipids and lipoproteins and the prevalence of risk for coronary heart disease in Canadian adults. Canadian Heart Health Surveys Research Group |
| Q70686786 | Potential health benefits of nutrition label changes |
| Q39703841 | Potential savings from reducing inequalities in health. |
| Q44053357 | Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels |
| Q45194574 | Quitline in smoking cessation: a cost-effectiveness analysis |
| Q40665059 | Risk-benefit assessment of drug treatment to prevent coronary heart disease. Estimating the benefits of risk factor modification |
| Q91667176 | Risks and Benefits of Alcohol Use Over the Life Span |
| Q33692481 | Risks and benefits of coronary angioplasty: the patients perspective: a preliminary study |
| Q44012124 | Screening for acquired cystic kidney disease: a decision analytic perspective |
| Q35411223 | Substantial potential for reductions in coronary heart disease mortality in the UK through changes in risk factor levels |
| Q72106650 | Surgery, drugs, lifestyle and hyperlipidemia |
| Q37722262 | The acute effect of smoking a single cigarette on vascular status, SpO2, and stress level |
| Q93506008 | The cholesterol controversy |
| Q78530338 | The development of a simulation model of the treatment of coronary heart disease |
| Q35200729 | The economics of smoking and cardiovascular disease |
| Q35557959 | The expiry date of man: a synthesis of evolutionary biology and public health |
| Q35175681 | The impact of the aging population on coronary heart disease in the United States |
| Q72594167 | The meaning of life expectancy: what is a clinically significant gain? |
| Q43774432 | The “intervention index”: Insufficient information |
| Q28219249 | Treatment of high blood pressure and gain in event-free life expectancy |
| Q73598683 | Using renal transplantation to evaluate a simple approach for predicting the impact of end-stage renal disease therapies on patient survival: observed/expected life span |
| Q34218142 | Waiting for the great leap forward |
| Q73705089 | [How relevant is statin therapy for clinical practice?] |
Search more.